Kornimate/medical-research-clean huggingface dataset:
diurnal variability in the regulation of beta-cell function and insulin sensitivity in overweight people

Conditions: Overweight

Summary: the purpose of this research study is to learn more about how our body produces sugar, breaks down fat for fuel, and makes insulin (the major hormone that controls the production of blood sugar and fat breakdown) during a 24-hour day and how body fat and muscle are involved in these processes.

the purpose of this study is to determine whether there are diurnal differences in postprandial beta-cell function and hepatic insulin sensitivity and the factors that influence these metabolic functions, including insulin signaling, adipose tissue and systemic inflammation, nicotinamide phosphoribosyltransferase (nampt)-mediated nicotinamide adenine dinucleotide(nad) biosynthesis, and sirtuin (silent mating type information regulation 2 homolog 1 (sirt1)) in overweight human subjects.

Eligibility criteria:
inclusion criteria: * females * 18-55 years old * bmi between 25.0-29.9 kg/m2 * must be sedentary (regular exercise \<1hour/week or \<2 times/week exclusion criteria: * regular exercise (\>1hour/week or \>2 times/week) * diabetes * severe organ dysfunction * smokers * severe hypertriglyceridemia (\>300 mg/dl) * medications that may alter the results of the study * pregnant * breastfeeding

Keywords: overweight
apathy in schizophrenia

Conditions: Schizophrenia; Apathy

Summary: apathy, defined as a quantitative reduction of voluntary, goal-directed behaviours (gdb), is a core component of negative symptoms. it has been suggested that the physiopathology of apathy is not a single entity but may be multiple, depending on which specific process or macrofunction is disrupted during completion of gdb. in line with this notion, levy and dubois proposed dividing apathic syndromes into three subtypes of disrupted processing: 'a-motivation', 'cognitive inertia', and 'uncoupling'. in schizophrenia, apathy has been associated with executive dysfunction, functional impairment and poor outcome. however, the neurobiological underpinnings of apathy in schizophrenia are poorly understood. primary objective: confirm that chronic schizophrenic patients are apathic compared to healthy volunteers secondary objectives: * investigate if apathy is related to a particular aspect of the disease (i.e. negative, positive symptomatology and/or deficit form) * investigate if apathy correlates with executive dysfunction * investigate if apathy is associated with a specific mechanism using an experimental task specially designed to investigate the different mechanism (i.e. 'a-motivation', 'cognitive inertia', and 'uncoupling') * investigate if there is a volumetric abnormality affecting the executive system in apathic schizophrenic patients * link these eventual volumetric abnormalities to prefrontal cortex-basal ganglia circuits according to a specific subtype of apathy in the apathic schizophrenic group


Eligibility criteria:
inclusion criteria (healthy volunteers): * male or female aged 20 to 55 years old included * under french public assurance system exclusion criteria (healthy volunteers): * personal history of neurological disorders * personal history of head injury * alcohol or substance abuse * under psychotropic drug * contraindication for mri inclusion criteria (schizophrenic patients): * male or female aged 20 to 55 years old included * under french public assurance system * diagnosis of schizophrenia according to the dsm-iv r criteria * duration of illness \> 5 years * clinical stability during the past 2 months (defined as no treatment modification or hospitalisation 2 months prior evaluation) exclusion criteria (schizophrenic patients): * schizo-affective disorder * personal history of neurological disorders * personal history of head injury * alcohol or substance abuse * contraindication for mri
18f-fdg pet/ct-based prognostic model for predicting outcome in patients with peripheral t-cell lymphoma

Conditions: Lymphoma, T-Cell, Peripheral

Summary: the purpose of this study is to evaluate whether 18f-fdg pet/ct-based prognostic model of ptcl can predict disease progression

in this study investigators develop a prognostic model based on 18f-fdg pet/ct and test its ability for prognostic value in patients with dlbcl. pet/ct scans evaluation using the liver suvmax as reference. positive lesions in pet were indicated as suvmax of residues higher than the threshold or new 18f-fdg avid lesions. 18f-fdg pet/ct-based prognostic model includes pet/ct image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in ptcl.

Eligibility criteria:
inclusion criteria: * newly diagnosed ptcl * treated using an anthracycline-containing regimen * minimal follow-up at 6 months after the completion of first-line treatment * complete medical history and clinicopathological data exclusion criteria: * secondary malignant disease * serious infection or inflammation (e.g., hiv) * primary central nervous system lymphoma * hepatic or renal dysfunction.

Keywords: lymphoma, t-cell, peripheral positron-emission tomography prognosis
biologically assisted core decompression of the femoral head using the perfuse instrument and biocue

Conditions: Avascular Necrosis of the Femoral Head

Summary: this study will evaluate the performance of biologically assisted core decompression with the perfuse instrument and biocue in patients with bone lesions in the femoral head. the study will explore the potential impact of patient demographics and baseline characteristics on post-operative outcomes.

this study will evaluate the performance of biologically assisted core decompression with the perfuse instrument and biocue in patients with bone lesions in the femoral head. the study will explore the potential impact of patient demographics and baseline characteristics on post-operative outcomes. the study will evaluate change in harris hip score (hhs) at 12 months after treatment. the change in avn lesion size will also be measured at 12 months after index treatment via mri. change in quality of life and pain measures will be measured at each follow-up. adverse events will also be recorded throughout the study. this study will follow patients for 5 years after initial treatment. data will be recorded in a online database that will be entered by the site or patient, depending on the report form. this database includes data checks to compare entered data against predefined rules for range. a risk-based monitoring plan will be put in place for source data verification.

Eligibility criteria:
inclusion criteria: * willing and able to comply with the study procedures * signed informed consent * untreated unilateral or bilateral bone lesion(s) of the femoral head associated with avn in need of biologically assisted core decompression. note:if bilateral untreated bone lesions of the femoral head associated with avn,both hips eligible and willing to undergo study treatment and follow-up * ≥ 3 months after arthroplasty (e.g., total, hemi) in the contralateral hip exclusion criteria: * pregnant or lactating * participating in another device or drug study * arco stage ≥ iii * unable to undergo mri of the study hip(s) * active, local or systemic infection
a study to determine the value of 18f-faza pet imaging in patients with breast cancer

Conditions: Breast Neoplasm

Summary: in about half the cases of breast cancer, there is hypoxic (no, or little oxygen) tissue present. hypoxic cells can be resistant to treatment and may cause increased tumour growth. this study will use 18f-faza pet scans before surgery or treatment to assess whether patients have hypoxic tumours. the results will be compared to tissue samples removed during surgery and to the distribution of 18f-fdg.

hypoxia or anoxia can be found in 50% of locally advanced breast carcinomas. assessment of pre-treatment in viva and in vitro hypoxia could allow patient selection for more aggressive therapy or clinical trails focused on targeting hypoxia. we will use the pet radiotracer 18f-faza to monitor hypoxia in the protocol. we will study pathological characteristics on the final tumour restriction specimen and correlate prognostic and predictive factors with pet scan data. tumour banking is optional.

Eligibility criteria:
inclusion criteria: 1. female ≥ 18 years of age. if female of child bearing potential and if outside of the window of 10 days since the first day of the 0last menstrual period, patient will be required to have a negative pregnancy test. 2. pathologically proven invasive duct carcinoma of the breast (fna or core biopsy), t1-t4(t ≥ 1.5 cm) 3. fluglucoscan injection and 18f-faza pet scans performed prior to treatment. 4. fluglucoscan injection and 18f-faza pet scans performed within 4 weeks prior to their definitive surgery if subject does not have neoadjuvant therapy. 5. able and willing to follow instructions and comply with the protocol 6. provide written informed consent prior to participation in the study. 7. ecog performance score ≤ 2 exclusion criteria: 1. previous malignancy or diagnosis less than ten (10) years ago. skin cancers (excluding malignant melanoma) and carcinoma in situ of the cervix are exceptions. 2. excisional biopsy of the primary breast tumour has been performed 3. women with an invasive carcinoma of the breast that is not predominantly of the invasive duct subtype 4. primary breast carcinoma previously treated. 5. women who are nursing or pregnant.

Keywords: 18f-faza 18f-fdg positron emission tomography cell hypoxia
ecological momentary mental assessment

Conditions: Person at Risk of Suicide

Summary: suicide is a major health problem that causes annually a million death worldwide. suicide and suicide attempts are preventable. a history of self-injuries or suicidal attempts are known to be the most important risk factor for death by suicide. suicidal ideation is also strongly correlated with suicide attempts. the development of smartphones applications offers new possibilities for data collection and transmission. moreover, the online help function, when a suicidal crisis occurs, is the most effective strategy for prevention of suicidal behavior. specific technologies have been developed to analyse behaviors and experiences of patients in a natural environment, in real life. that is the goal of ecological momentary assessment. the aim of the study is to develop an algorithm to assess and predict the risk of suicidal event occurrence, in order to detect as soon as possible the signs of suicidal crisis. emma will be the first application in french, meeting the recommendations for health applications, developed by experts on suicidal behavior and in collaboration with patients which aims to predict suicidal risk. a subsequent study, conducted on a larger population, should allow to validate the predictive algorithm of emma. long-term goal is to improve the care of patients at risk for suicidal behavior.

100 patients having recently attempted suicide or having suicidal ideation will be recruited. they will be asked to use the application emma during 6 months and will be followed up during this period. an optional qualitative study conducted on 25 patients will allow to evaluate more finely their subjective experience of the use of the application. initial visit (inclusion) : clinical, biological and neuropsychological assessment and installation of the application emma. first visit (1st month) and second visit (3rd month) : clinical assessment last visit (6th month) : clinical, biological and neuropsychological assessment and optional qualitative interview.

Eligibility criteria:
inclusion criteria: * recent suicidal attempt (\< 8 days) or suicidal ideation score ≥ 2 (idsc-30 scale) * more than 18 years old * able to understand nature, aims, and methodology oh the study * to own a smartphone exclusion criteria: * refusal to participate * patient on protective measures (guardianship or trusteeship) * deprived of liberty subject (administrative decision) * subject in exclusion period for another protocol * not affiliated to a social security agency * unable to understand and/or answer a questionnaire

Keywords: psychiatry suicide prediction smartphone application ecological momentary assessment
beacon sensors and telerehabilitation to assess and improve use of devices (best-aid) for low vision

Conditions: Low Vision; Low Vision Aids

Summary: one goal of this research is to conduct a non-inferiority trial of telerehabilitation versus in-office care to provide follow-up training to individuals with low vision to enhance their quality of life by using magnification devices and/or visual assistive mobile apps for important daily activities, such as reading and/or other valued tasks. this is a high priority given the increasing prevalence of low vision, paucity of low vision rehabilitation providers, and barriers related to access to care, such as transportation and geography, which can be essentially eliminated with telerehabilitation. another goal of this project is to determine whether significant changes in environmental data collected by bluetooth low energy beacon sensors can be used as a solution to monitor and indicate when low vision patients' have abandoned the use of their magnification devices, which has the potential to substantially enhance patient management by providing timely low vision rehabilitation services.


Eligibility criteria:
inclusion criteria: * adults with any level of vision loss due to any ocular disease who are age 18 and older, and who have received new magnification device(s) for the first time (i.e., hand-held optical magnifiers, portable electronic video magnifiers, high near add powers of +4.00 or greater, visual assistive mobile apps for their smartphone/tablet, some stand magnifiers and cctvs) from one of our participating low vision rehabilitation sites at the four academic centers and one private practice. exclusion criteria: * schedules not permitting participation in planned study visits (including planning to move far from their clinical provider's office within the first 4-months of the study (i.e., cannot attend in-office visits) or take extended vacation that would not allow them to complete study procedures during the first four months of the study period), * inability to understand study procedures or communicate responses to visual stimuli in a consistent manner (greater than mild cognitive impairment as per tics), * substance abuse, * significant hearing loss (unable to hear communication by phone or via videoconferencing), * significant medical condition likely to limit participation or lifespan, * individuals who require other types of lvr training or intervention (e.g., psychosocial). * for bluetooth low energy beacon sensors, exclusion would occur if their magnifier device has features that would not work in conjunction with the beacon sensors: (1) hands-free and do not have a place where the patient's hand is holding the device during use (therefore, they would not register a significant change in temperature), (2) no surface area of at least 1"x1" to which the beacon sensor could be attached without interfering with the device, or (3) use of visual assistive mobile apps only.
influenza vaccine post allogeneic transplant

Conditions: Hematopoietic Stem Cell Transplant; Hematologic Malignancy

Summary: study design: this is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (hsct) recipients who receive one vaccine or two vaccine doses one month apart. in addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.


Eligibility criteria:
inclusion criteria: * patient population * hsct recipients who are greater than 60 days post transplant. * age 6 months and older who are greater than 60 days post post allogeneic hematopoietic cell transplant * show neutrophil recovery, platelet count \> 50,000/mm3 (may be transfused), no known disease relapse * no history of previous allergic reaction to influenza vaccine, known egg allergy or guillan-barre syndrome * no flu vaccine in previous 4 months, no campath in previous 6 months, no intravenous immune globulin (ivig) in previous 3 months * controls: * age 18 to 50 years * no history of previous allergic reaction to influenza vaccine, known egg allergy or guillan-barre syndrome * no flu vaccine in previous 4 months

Keywords: influenza vaccine
mucosal impedance in pediatric population

Conditions: Gastroesophageal Reflux Disease (GERD); Eosinophilic Esophagitis (EoE); Functional Dyspepsia

Summary: our hypothesis is that patients with gerd and/or eosinophilic esophagitis (ee) have lower esophageal impedance measurements when compared to patients who do not have gerd or ee.

the overall goal of this project is to develop and assess a novel, inexpensive, minimally invasive technology to detect mucosal damage based on mucosal conductivity changes in the pediatric population. the study is based on preliminary work between sandhill scientific, inc. and our adult gastroenterology department. they have collaborated to create a novel, minimally invasive mucosal impedance (mi) test (proprietary technology) based on animal studies which have shown esophageal tissue exposed to acidic and weakly acidic injurious agents causes dilation of intercellular spaces and loss of tight junctions along the squamous epithelial lining of the esophagus and results in measurable decreased baseline impedance.9 adult studies have confirmed the correlation between decreased impedance and diseased tissue, however this has not been studied in children. we hypothesize that pediatric patients with histologic damage seen in gerd and eoe will have mucosal changes resulting in decreased electrical impedance compared to those with normal histology. we propose that this technology will accurately and reliably measure the mucosal consequence of chronic esophageal exposure to injurious gastroduodenal agents or food allergens. thus, this test would serve as a minimally invasive screening tool for gerd and eoe prior to endoscopy, and allow longitudinal monitoring of mucosal response to therapy.

Eligibility criteria:
inclusion criteria: * patients between 1 year and 18 years of age * patients who are undergoing standard of care upper endoscopy and biopsy for complaints of dyspepsia exclusion criteria: * families unable to give informed consent/assent; * patients with other active comorbid conditions including cardiac disease, pulmonary disease (excluding asthma), significant motility conditions

Keywords: gerd egd ph testing eosinophilic esophagitis impedance testing
the effect of losartan in bicuspid aortic valve patients

Conditions: Bicuspid Aortic Valve; Thoracic Aortic Aneurysm

Summary: the specific aims of this study are to: * establish baseline levels of circulating mmp-2 and -9 , timp-1and- 2 and tgfb levels in individuals with bicuspid aortic valve and ascending aortic or aortic sinus measurements \>40mm. * assess the effect on mmp levels during treatment with losartan, an angiotensin ii receptor blocking agent. * in the setting of losartan therapy for one year, evaluate the response of mmp levels in these patients, and clinical outcomes including effects on aortic growth rate


Eligibility criteria:
inclusion criteria: * adults \>age 18 years and \< 65 years old * able to give informed consent * presence of a bicuspid aortic valve (functional or true bicommisural)and ascending aorta or sinus of valsalva \>4.0cm * no contraindications to treatment with losartan, an angiotensin ii receptor blocker * able to safely participate in a 4 week drug washout period if currently taking an angiotensin ii receptor blocker or ace inhibitor. exclusion criteria: * unable to safely take losartan due to one or more of the following: * hypersensitivity to losartan or other angiotensin receptor blockers * pregnancy * nursing mothers * history of angioedema * hypotension - chronically volume depleted patients * hepatic or renal impairment (cr\>1.5mg/dl) * hyperkalemia (k+\>4.8) * renal artery stenosis * severe congestive heart failure (class iii-iv) * currently taking potassium supplements or salt substitutes containing potassium * currently taking lithium * prior surgical intervention to aorta or aortic valve * unable or unwilling to give informed consent and follow up with study activities * currently taking an angiotensin receptor blocker or ace inhibitor specifically for hypertension and are therefore unable to or are unwilling to participate in a 4 week drug washout period. * females of child bearing who are unwilling to practice adequate birth control throughout the study.
interstitial lung disease research unit biobank

Conditions: Interstitial Lung Disease; Sarcoidosis; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Hypersensitivity Pneumonitis

Summary: establish a interstitial lung disease (ild) registry and biorepository to lead towards a further understanding of the disease.

the university of kansas ild and rare lung disease clinic sees hundreds of new patients per year. the investigators would like to leverage this resource to develop an interstitial lung disease research unit (ildru) repository and database to help develop new methods for early diagnosis, uncover underlying genetic and environmental risk factors, as well as potential treatment targets in the broad range of interstitial lung diseases and rare lung diseases (rld).

Eligibility criteria:
inclusion criteria: 1. the participant is a patient at tukhs or has agreed to participate in a study approved by the kumc human research protection program (hrpp) 2. the participant is being followed for the presence of autoimmune disease, ild or other rare lung diseases at tukhs. 3. the participant is ≥ 18 years of age. 4. the participant has signed an approved consent for this study (living patients only)

Keywords: interstitial lung disease sarcoidosis idiopathic pulmonary fibrosis pulmonary fibrosis hypersensitivity pneumonitis
function following thumb mp fusion and ip fusion

Conditions: Osteoarthritis

Summary: this study is to determine function following simulated thumb metacarpophalangeal (mp) and thumb interphalangeal (ip) joint fusion. the investigators want to determine the functional limitation created by mp and ip joint fusion. 20-30 volunteers will be fitted for custom molded orthoplast splints immobilizing either the mp or ip joint. the volunteers will then be taken through multiple tests including lateral pinch strength, tip pinch, grip strength, grooved pegboard test time, and jebson taylor test. each patient will be tested without a splint, with their mp joint immobilized and with their ip joint immobilized. the results of this study can be used for patient education before surgery in order to help them make informed decisions as well as manage expectations. it can also serve as a decision aid in pinch restoration in the context of ulnar nerve palsy.


Eligibility criteria:
inclusion criteria: * patient is a healthy volunteer * patient is willing and able to review and sign a study informed consent form exclusion criteria: * any subject who does not want to voluntarily participate.